GLP-1 drugs have moved from niche treatment to major budget issue. For employers, the challenge is clear: demand is rising, list prices are high, and open-ended coverage can push pharmacy trend far past plan targets.
Coverage has expanded, but it is still selective. In 2025, KFF found that 19% of employers with 200 or more workers covered GLP-1s for weight loss in their main plan, while 43% of employers with 5,000 or more workers did. SHRM also reported that 23% of employers covered GLP-1s for type 2 diabetes and or weight management, and one 2025 dataset showed GLP-1 spend climbing about 50% year over year. That pressure is why many leaders are tightening rules instead of opening the floodgates.
TL;DR: Employers do not need to choose between unlimited GLP-1 coverage and no coverage at all. The stronger approach uses plan rules, PBM review, employee education, and lifestyle support to protect access for people with real clinical need while keeping pharmacy spend in check.
Key Takeaways
- GLP-1 demand is rising fast, and many drugs still cost hundreds to over $1,000 per month depending on product, dose, and purchasing path.
- More employers now cover drugs like Ozempic, Wegovy, Mounjaro, and Zepbound, but most use tighter controls.
- Prior authorization helps confirm medical need and reduce low-value use.
- Step Therapy can lower costs, and some employers report savings near 25%, although results vary by Plan Design.
- PBM rebates matter, but Net Cost matters more than list price.
- Education and lifestyle support improve understanding, engagement, and responsible use.
What is driving GLP-1 drug costs so high for employers? #
The pressure starts with price. In 2026, common GLP-1 list prices often sit above $1,000 per month, although member out-of-pocket costs may be lower through insurance or manufacturer programs. For employers, the larger issue is total plan spend, not the coupon price an employee sees at the pharmacy counter.
Demand is the second force. More employees now ask for GLP-1s for diabetes, obesity, or both. Because treatment often lasts months or years, costs do not fade after a short burst. They stack up month after month, and that can hit pharmacy trend, Stop-Loss renewals, and budget planning at the same time.
That pattern fits the broader story of rising costs of specialty drugs in health plans. A small number of high-cost claims can change the whole plan.
Coverage is growing, but so are restrictions #
More employers are covering GLP-1s, especially large groups. Still, coverage growth does not mean easy access. Most plans now use diagnosis rules, BMI thresholds, prior authorization, refill checks, and sometimes duration limits.
Broader coverage without guardrails can turn a pharmacy trend problem into a Plan Design problem.
That matters for HR and finance leaders. A plan can cover GLP-1s and still manage them closely. In many cases, that is the difference between a controlled benefit and a runaway expense.
Short-Term pharmacy spend often rises before long-Term savings show up #
GLP-1s may improve weight, blood sugar, and other health markers over time. Some reports point to possible medical savings later, especially when treatment is well-targeted and sustained.
However, most employers feel the pharmacy spike first. KFF reported that 64% of large firms said GLP-1 coverage increased drug spending moderately or greatly. Near-Term savings in medical claims may not arrive soon enough to offset that jump. Therefore, leaders need a plan built for today’s cash flow, not only tomorrow’s promise.
How employers can control GLP-1 costs without shutting the door on care #
A good strategy protects access for people who truly need treatment. At the same time, it lowers waste and improves oversight. That balance creates more sustainable costs and more measurable outcomes.
Prior authorization helps confirm medical need #
Prior authorization asks the prescriber to show why the drug fits the member’s condition and the plan’s rules. That review can confirm diagnosis, prior treatment history, BMI criteria, or clinical risk.
This does not block care when it is used well. Instead, it helps prevent off-label use, duplicate therapy, and casual prescribing that the plan never intended to cover. For employers, that means tighter alignment between benefit design and actual use.
Step Therapy can lower costs by moving lower-cost options first #
Step Therapy creates an ordered process. A member may need to try lifestyle support, lower-cost medication, or another appropriate treatment before moving to a high-cost GLP-1.
Some employer plans report savings around 25% with Step Therapy, but the number depends on the population, rules, and clinical exceptions. The key is restraint. If Step Therapy is too rigid, employees get frustrated and care can stall. If it is evidence-based, it can lower spend without harming access.
PBM contract review can uncover better net pricing #
List price is only part of the story. Rebates, Formulary position, Spread Pricing, clinical management fees, and pass-through terms all affect true cost. That is why employers should review PBM contracts with the same care they give medical renewals.
JA often helps employers look beyond headline discounts and focus on Net Cost, preferred products, and plan-specific performance. Stronger annual renewal tips for pharmacy benefit negotiations can improve visibility before costs harden into the next cycle.
Why employee education and lifestyle support are part of cost control #
Plan rules alone will not solve this problem. Employees need clear knowledge about who qualifies, what the approval process looks like, and why lifestyle support still matters.
Lifestyle programs can improve results and reduce avoidable spend #
Nutrition guidance, movement support, behavior coaching, and weight management programs help employees build habits that support better outcomes. In some cases, that support may delay the need for a GLP-1 or improve success after treatment starts.
This is where the human side matters. A benefits decision affects more than a spreadsheet. It touches the employee managing diabetes, the parent trying to improve long-Term health, and the family paying for care month after month.
Clear communication helps employees understand what comes next #
Confused employees often feel denied, even when the plan is following clear rules. Better communication lowers that friction. Explain eligibility, prior authorization steps, refill requirements, and the role of lifestyle changes in plain language.
JA believes communication is part of cost control because informed employees use benefits more wisely. That improves trust, supports engagement, and creates stronger ROR over time.
A balanced GLP-1 strategy looks different for every employer #
There is no off-the-shelf answer here. A manufacturing firm with a tight budget will not make the same choice as a large employer competing hard for talent. The right answer depends on claims data, workforce health needs, and risk tolerance.
Start with your claims data, workforce needs, and risk tolerance #
Before changing coverage, review utilization, diagnosis mix, refill patterns, and pharmacy trend. Benchmarking also helps. Tools like benchmarking prescription pharmacy plan costs can show how your plan compares with peers and where pressure is building.
Use a long-Term benefits strategy instead of reacting to the latest trend #
Quick fixes often create new problems. A better approach combines coverage criteria, PBM oversight, member communication, and regular reporting. That gives leaders clearer choices and a steadier Plan Year.
GLP-1s are expensive, but they do not have to break the plan. The best strategy uses medical necessity, smart purchasing, and steady communication to support employees who need care while protecting the health plan’s future.
